Eltrombopag For Immune Thrombocytopenic Children in a Single Region

  • Göksel LeblebisatanEmail author
  • Yurdanur Kilinc
  • Metin Cil
  • İlgen Sasmaz
  • Ayse Ozkan
Original Article


Objective Child patients of chronic thrombocytopenic purpura with severe and resistant thrombocytopenia were evaluated to observe whether their clinical or laboratory states improve by one of the thrombomimetic therapeutic agent called Eltrombopag as in adults in a single center of different country from previous studies. Materials and Methods Nineteen patients with chronic immune thrombocytopenia were treated with Eltrombopag to dose in international guidelines. Results Approximately half (11/19:58%) of the patients benefitted from the treatment with Eltrombopag either by an increase of platelet levels at safe levels with a decrease in the frequency of bleedings which needed rescue treatment. Conclusion Thrombomimetic treatment options have strengthened the clinician’s hand where the regular treatment options became insufficient.


Immune thrombocytopenia Children Eltrombopag 


Compliance with Ethical Standards

Conflict of interest

All authors declare that they have no conflict of interest.


  1. 1.
    Ramaswamy K et al (2014) Thrombopoietic agents for the treatment of persistent and chronic immune thrombocytopenia in children. J Pediatr 165(3):600–605CrossRefGoogle Scholar
  2. 2.
    Burness Celeste B, Keating GM, Garnock-Jones KP (2016) Eltrombopag: a review in paediatric chronic immune thrombocytopenia. Drugs 76(8):869–878CrossRefGoogle Scholar
  3. 3.
    Bolton-Maggs Paula (2003) Severe bleeding in idiopathic thrombocytopenic purpura. J Pediatr Hematol Oncol 25:S47–S51CrossRefGoogle Scholar
  4. 4.
    Grainger JD et al (2015) Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial. Lancet 386(10004):1649–1658CrossRefGoogle Scholar
  5. 5.
    Ali S et al (2017) Eltrombopag for secondary failure of platelet recovery post‐allogeneic hematopoietic stem cell transplant in children. Pediatr Transplant 21(6). CrossRefGoogle Scholar
  6. 6.
    Ma J et al (2016) Clinical study of pulsed high-dose dexamethasone treatment in 38 children with primary immune thrombocytopenic purpura. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 37(10):912–915PubMedGoogle Scholar
  7. 7.
    Naithani Rahul, Sachdev Mansi, Uttam Rajiv (2016) Successful use of eltrombopag in a child with hurler syndrome after haploidentical hematopoietic stem cell transplantation. J Pediatr Hematol/Oncol 38(2):163–164CrossRefGoogle Scholar
  8. 8.
    Özdemirkıran F et al (2015) Eltrombopag for the treatment of immune thrombocytopenia: the aegean region of turkey experience. Turkish J Hematol 32(4):323CrossRefGoogle Scholar
  9. 9.
    Grainger JD, Thind S (2017) A practical guide to the use of eltrombopag in children with chronic immune thrombocytopenia. Pediatr Hematol Oncol 34(2):1–17CrossRefGoogle Scholar
  10. 10.
    Elgebaly AS et al (2016) Tolerability and efficacy of eltrombopag in chronic immune thrombocytopenia: meta-analysis of randomized controlled trials. Clinic Appl Thrombosis/Hemostasis 23(8):928–937CrossRefGoogle Scholar
  11. 11.
    Neunert C et al (2016) Thrombopoiet in receptor agonist use in children: data from the pediatric ITP consortium of North America ICON2 study. Pediatr Blood Cancer 63(8):1407–1413CrossRefGoogle Scholar
  12. 12.
    Gerrits AJ et al (2015) Effects of eltrombopag on platelet count and platelet activation in Wiskott-Aldrichsyndrome/X-linkedthrombocytopenia. Blood 126(11):1367–1378CrossRefGoogle Scholar
  13. 13.
    Bussel JB et al (2015) Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study. Lancet Haematol 2(8):e315–e325CrossRefGoogle Scholar
  14. 14.
    Mazzucconi MG et al (2017) Tpo‐ras in pitp: description of a case series and analysis of predictive factors for response. Eur J Haematol 98(3):242–249CrossRefGoogle Scholar
  15. 15.
    Suntsova EV et al (2017) Bleeding tendency and platelet function during treatment with romiplostim in children with severe immune thrombocytopenic purpura. Int J Hematol 105(6):841–848CrossRefGoogle Scholar
  16. 16.
    Wang X-L, Li A-M (2016) Successful use of eltrombopag in a child with refractory immune thrombocytopenia: case study and literature review. Blood Coagul Fibrinol 27(7):825–827CrossRefGoogle Scholar
  17. 17.
    Garzon AM, Mitchell WB (2015) Use of thrombopoietin receptor agonists in childhood immune thrombocytopenia. Frontiers Pediatr 3:70CrossRefGoogle Scholar
  18. 18.
    Scully M et al (2012) Eltrombopag named patient programme for patients with chronic immune thrombocytopenia. B J Haematol 157(2):259–260CrossRefGoogle Scholar

Copyright information

© Indian Society of Hematology and Blood Transfusion 2018

Authors and Affiliations

  1. 1.Department of Pediatric HematologyÇukurova University Medical FacultyAdanaTurkey
  2. 2.Adana Numune Research and Education Hospital, Pediatric Hematology-OncologyAdanaTurkey

Personalised recommendations